This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q99.2 | Special Copayment Reduction: V245 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | Adult onset possible — intellectual disability and behavioral abnormalities due to the full mutation (>200 CGG repeats) present mainly in childhood, but in premutation (55–200 CGG repeats) carriers, FXTAS (fragile X-associated tremor/ataxia syndrome, mainly in men aged 50 or older) and FXPOI (fragile X-associated primary ovarian insufficiency) present in adulthood, after middle age. |
| 1. History | 1943 Martin and Bell family report → 1969 Lubs discovers fragile site on X chromosome → 1991 FMR1 gene identified and CGG repeat expansion mechanism elucidated → 2001 FXTAS discovered → current research on mGluR5-targeted therapy. |
| 2. Causes | CGG trinucleotide repeat expansion in the 5' untranslated region of the FMR1 gene (Xq27.3): normal <45 repeats, premutation 55–200, full mutation >200. In the full mutation, FMR1 methylation → transcriptional silencing → loss of FMRP. |
| 3. Genetics | X-linked dominant (effectively). Unstable CGG repeat number → allele expansion (repeat number increases on intergenerational transmission). Maternal premutation (55–200) → expansion to full mutation (>200). FXTAS: toxic accumulation of premutation FMR1 mRNA. FXPOI: premature ovarian failure in about 20% of premutation women. |
| 4. Epidemiology | Full mutation: about 1 in 4,000 males, about 1 in 8,000 females. Premutation: about 1 in 800 males, about 1 in 250 females. The most common inherited intellectual disability. The most common single-gene cause of autism spectrum disorder. |
| 5. Pathophysiology | Loss of FMRP → disinhibition of the mGluR5 pathway → excessive synaptic protein translation → abnormal synaptic plasticity → intellectual disability, autism spectrum. Premutation: excessive accumulation of FMR1 mRNA → RNA toxicity → neuronal death (FXTAS). Overload of ovarian granulosa cells (FXPOI). |
| 6. Symptoms | Males: mild to moderate intellectual disability (IQ 20–70), autism spectrum, language delay, hyperactivity, anxiety. Females: mild cognitive impairment to normal. FXTAS: intention tremor, cerebellar ataxia, parkinsonian symptoms, dementia. FXPOI: premature ovarian failure before age 40. |
| 7. Signs | Large ears, long face, prominent forehead and jaw, macroorchidism (after puberty). Skin hyperextensibility, joint laxity. Mitral valve prolapse. FXTAS: middle cerebellar peduncle white matter lesions on MRI (MCP sign). |
| 8. Screening | Newborn screening (some states/countries), FMR1 molecular testing in children with developmental delay, autism, or intellectual disability. Cascade screening of the extended family when a premutation/full mutation is identified in a family. Older men with suspected FXTAS. |
| 9. Diagnosis | Measurement of FMR1 CGG repeat number (PCR + Southern blot). Methylation analysis (confirms loss of function in full mutation). Brain MRI (FXTAS). Developmental assessment, autism screening tools. |
| 10. Treatment | No curative treatment (research on restoring FMRP ongoing). Symptomatic treatment: autism and behavioral therapy, speech therapy, stimulants (ADHD), anxiolytics. FXTAS: immunosuppression, clonazepam. FXPOI: estrogen supplementation. |
| 11. Prognosis | Full-mutation males: most cannot live independently. Females: mild, independent living possible. FXTAS: progressive, poor prognosis. Early intervention is important for improving function. |
| 12. Prevention | Genetic counseling, prenatal diagnosis (CVS/amniotic fluid CGG analysis), preimplantation genetic testing (PGT-M). Cascade screening of premutation families. Early detection of FXTAS. |
| 13. References | 10 references (PMID / DOI) |
The history of fragile X syndrome begins in 1943, when the British physicians James Purdon Martin and Julia Bell reported a family showing intellectual disability with X-linked inheritance. This report described intellectual disability inherited in an X-linked manner across two generations of males, but the cause was not identified. The syndrome was subsequently also called Martin-Bell syndrome.
In 1969, the Canadian geneticist Herbert Lubs discovered that a fragile site appeared, depending on cell division conditions, at the distal end of the long arm of the X chromosome (Xq27.3) in males with intellectual disability. This fragile site was observed more readily under folate-deficient culture conditions, and this chromosome was named "Marker X" or "fragile X." However, this discovery did not attract wide attention at the time.
In 1977, Grant Sutherland confirmed that the fragile site could be observed more reliably using folate-deficient culture medium, making cytogenetic diagnosis of fragile X syndrome possible. During this period, it was recognized as one of the most common genetic causes of intellectual disability. 1991 was a landmark year in fragile X syndrome research, when two research groups, including Verkerk et al., almost simultaneously identified the FMR1 (Fragile X Mental Retardation 1) gene and established that when the CGG trinucleotide repeat sequence in the 5' untranslated region (5' UTR) is abnormally expanded (>200 repeats), the gene becomes methylated and silenced, leading to loss of FMRP (FMR1 Protein).
In 2001, Hagerman et al. described FXTAS (Fragile X-associated tremor/ataxia syndrome), a new syndrome characterized by intention tremor and cerebellar ataxia in older male carriers of the premutation (55–200 CGG repeats). It was subsequently also established that premature ovarian failure (FXPOI) is increased in female premutation carriers, making it clear that the spectrum of CGG repeat expansion in the FMR1 gene causes a variety of clinical syndromes beyond simple intellectual disability. Research on fundamental treatment through modulation of the mGluR5 (metabotropic glutamate receptor 5) pathway is currently active, and gene therapy (viral vector-based FMR1 delivery) and antisense oligonucleotide (ASO) therapy are also being explored at the preclinical and phase 1 clinical stages.
Fragile X syndrome is caused by abnormal expansion of the CGG trinucleotide repeat sequence in the 5' untranslated region (5' UTR) of the FMR1 gene, located on the long arm of the X chromosome (Xq27.3). In normal individuals, the CGG repeat number is about 6–44 (mean about 30) and remains stable within this range.
The clinically meaningful classification of CGG repeats is as follows.
CGG repeat expansion is characterized by conversion to a full mutation particularly from maternal premutations. Paternal premutations very rarely expand to full mutations, and all daughters who receive a paternal premutation will carry the premutation. The larger the repeat number, the higher the likelihood of expansion to a full mutation in the next generation (almost always if the repeat number is >100). This characteristic is called anticipation.
The inheritance pattern of fragile X syndrome is classified as X-linked dominant with incomplete penetrance, but in practice it shows a complex inheritance pattern.
Because males have only one X chromosome, symptoms almost always appear if they carry a full mutation. In females, even if one of the two X chromosomes carries a full mutation, the other normal X chromosome supplies some FMRP, so symptoms are often mild or absent. The more the X-inactivation ratio (active X ratio) favors the normal X chromosome, the milder the symptoms.
FMRP (FMR1 protein) is an mRNA-binding protein that suppresses the translation of many mRNAs at synapses (mainly those involved in dendritic maturation and synaptic protein translation). When FMRP is lost, synaptic protein translation induced by mGluR5 (group I metabotropic glutamate receptor 5) stimulation is excessively activated, long-term synaptic depression (LTD) is abnormally increased, and synaptic plasticity is impaired. Clinical trials of mGluR5 antagonists targeting this mechanism (fenobam, AFQ056, etc.) have been conducted, but they have not yet reached the level of clinical application.
The molecular mechanism of FXTAS is not loss of FMRP but RNA toxicity due to excessive accumulation of premutation FMR1 mRNA. The excess mRNA forms intranuclear inclusions, causing toxicity in neurons and astrocytes, and neuronal death in the cerebellum and cerebral subcortical white matter leads to tremor, ataxia, parkinsonian symptoms, and cognitive decline. FXPOI arises through a mechanism in which premutation mRNA causes toxicity to ovarian granulosa cells, accelerating follicle loss.
Fragile X syndrome is the most common inherited intellectual disability and the most frequent single-gene cause of autism spectrum disorder. The prevalence of the full mutation is estimated at about 1 per 4,000 males and about 1 per 8,000 females. The frequency of premutation carriers is much higher, estimated at about 1 per 250–300 females and about 1 per 800 males.
Worldwide, there are estimated to be about 1 million patients with fragile X syndrome due to the full mutation (about 500,000 males + about 500,000 females), and premutation carriers are estimated to number in the millions. About 2–3% of males with autism spectrum disorder and about 5–6% of males with intellectual disability of unknown cause are diagnosed with fragile X syndrome. FXTAS develops at age 50 or older in about 30–40% of male premutation carriers and in about 8–16% of female premutation carriers.
FXPOI occurs in about 20% of female premutation carriers, which is markedly higher than the frequency of premature ovarian failure in the general population (about 1%). The proportion of FMR1 premutations found in FXPOI patients is about 2% in sporadic POI without family history and about 12–15% in familial POI. Incidence may vary somewhat by ethnicity, but it is distributed worldwide. In Korea, it is registered under rare disease Special Copayment Reduction V245 (Q99.2).
The core pathophysiology of fragile X syndrome is synaptic dysfunction due to loss of FMRP. FMRP normally functions as a repressor that binds mRNA in dendrites and suppresses protein translation. The main target mRNAs of FMRP include dozens of proteins involved in synaptic development and plasticity, such as MAP1B, CaMKII, Arc/Arg3.1, PSD-95, GluA1/GluA2 (AMPA receptor subunits), SHANK, and NLGN.
When FMRP is lost, downstream signaling of mGluR5 (metabotropic glutamate receptor 5) becomes hyperactivated. Normally, mGluR5 stimulation induces translation of FMRP target mRNAs but is appropriately regulated by FMRP. When FMRP is lost, this control disappears, synaptic protein translation becomes excessive, and long-term synaptic depression (mGluR-LTD) is abnormally increased. At the same time, GABA inhibitory signaling decreases, increasing neuronal excitability, which forms the basis of hyperactivity, anxiety, and the predisposition to epilepsy (seizures in about 20%).
Abnormal synaptic morphology: in animal models of fragile X syndrome, the number of dendritic spines increases, but their morphology is immature (thin, long immature spines) and functional synapse formation is insufficient. This is understood to be because FMRP target proteins are overexpressed, impairing synaptic maturation. This synaptic abnormality is regarded as the morphological basis of intellectual disability and autism spectrum disorder.
The pathophysiology of FXTAS is RNA toxicity of premutation FMR1 mRNA. In the premutation, the CGG repeat expansion fails to induce methylation, so FMR1 transcription actually increases (2–8 times normal), and this excess mRNA nonspecifically sequesters proteins such as hnRNP A2, DROSHA, DICER, and Lamin A/C, forming intranuclear inclusions and disrupting RNA processing functions. As a result, cerebellar degeneration, white matter damage of the middle cerebellar peduncle, and cerebral subcortical white matter damage progress.
The clinical symptoms of fragile X syndrome vary according to the CGG repeat number (full mutation vs. premutation), sex (male vs. female), and, in females, the X-inactivation pattern.
Intellectual disability is most often mild to moderate (mean IQ about 40–55), and severe intellectual disability also occurs in about 25%. Language delay is pronounced, characterized by echolalia, rapid speech, irregular speech rate, and repetitive language patterns. Autism spectrum disorder is diagnosed in about 50–67% of male patients. Gaze avoidance, social anxiety, and stereotyped behaviors are common. Attention-deficit/hyperactivity disorder (ADHD) is present in about 70–80%. Anxiety disorders (social anxiety, generalized anxiety) are common. Epilepsy occurs in about 10–20% and generally follows a benign course. Physical examination: large ears (prominent ears), long face, prominent forehead and jaw, macroorchidism after puberty (testicular volume >30 mL). Joint hypermobility, skin hyperextensibility.
Much more variable and milder than in males. About 50% have intelligence in the normal range, while the remaining 50% have mild intellectual disability (mean IQ about 80–85), learning disabilities, reduced mathematical ability, and reduced executive function. Anxiety, mood disorders, and social difficulties are common.
FXTAS (mainly male carriers, age 50 or older): intention tremor (the earliest symptom), cerebellar ataxia (gait instability), peripheral neuropathy (pain, paresthesia), autonomic dysfunction, parkinsonian symptoms (rigidity, bradykinesia), cognitive decline (executive function, memory), and behavioral abnormalities. Increased white matter signal in the middle cerebellar peduncle (MCP) on brain MRI (MCP sign) is a characteristic imaging finding. FXPOI (female premutation carriers): symptoms of premature ovarian failure before age 40 (irregular menstruation, hot flashes, infertility).
The main clinical signs of fragile X syndrome are described by system.
Long face (dolichocephaly), prominent forehead, large, prominent ears, prominent jaw, high-arched palate, strabismus. Hyperextensible skin is observed in some. Joint hypermobility (hyperextensible joints, especially finger joints). Flat feet (pes planus).
Macroorchidism is a highly specific physical sign of fragile X syndrome, with testicular volume enlarging to 30–50 mL or more after puberty. This is due to increased testicular cell division caused by loss of FMRP and is unrelated to malignant change.
Findings of intellectual disability on developmental testing (Bayley, Stanford-Binet, WISC, etc.). Positive autism screening tools (ADOS-2, ADI-R). EEG abnormalities (centrotemporal spikes, 4 Hz waveforms). FXTAS: intention tremor on neurological examination and cerebellar ataxia on gait testing. MCP sign (bilateral high signal intensity in the MCP on brain MRI T2/FLAIR).
Mitral valve prolapse is reported to be observed in about 50–80%, but it is mostly mild and of limited clinical significance. Aortic dilation is rarely present.
Elevated FSH, elevated LH, low estradiol, low AMH. Reduced ovarian size and reduced follicle count on ultrasound. Reduced bone mineral density.
Screening and diagnosis of fragile X syndrome take place through various clinical pathways.
FMR1 molecular testing is performed in the following situations: (1) intellectual disability of unknown cause, especially in boys, (2) search for a genetic cause after a diagnosis of autism spectrum disorder, (3) boys with developmental delay (language, motor), (4) when a family member is a carrier of an FMR1 mutation. In the United States and some European countries, including FMR1 in newborn screening programs is under discussion.
When FXTAS is suspected (an unexplained combination of tremor + ataxia in men aged 50 or older, with a family history of boys with intellectual disability or autism spectrum disorder or women with premature ovarian failure). FMR1 analysis after family history review in patients with premature ovarian insufficiency (POI). Measurement of FMR1 repeat number for reproductive counseling in female premutation carriers.
When an FMR1 full mutation or premutation is identified in one family member, cascade screening of other family members is recommended. Children of women with a maternal premutation must undergo FMR1 analysis.
Fragile X syndrome is confirmed by quantitative analysis of FMR1 CGG repeat number. The diagnostic process is as follows.
Step 1: PCR-based measurement of CGG repeat number. Standard PCR is suitable for measuring repeat numbers in the normal range and up to the premutation (~200 repeats). In the full mutation, the CGG repeats are so numerous that standard PCR amplification is difficult, so triplet-primed PCR (TP-PCR) is used. TP-PCR shows high sensitivity for full mutation screening.
Step 2: Southern blot analysis. Essential for confirming a full mutation and determining methylation status. After digestion with EcoRI and EagI (a methylation-sensitive restriction enzyme), blotting with an FMR1 probe is performed to estimate repeat size and determine methylation. It is also needed to identify mosaicism (mixture of full mutation + premutation, or full mutation + normal).
Supplementary tests: FMR1 immunohistochemistry (confirms FMRP protein expression, particularly using blood smears or hair root cells). Brain MRI (aids FXTAS diagnosis: T2/FLAIR hyperintensity in the MCP and cerebral subcortical white matter, cerebellar atrophy). Developmental and cognitive assessment (severity of intellectual disability, autism spectrum diagnosis, adaptive behavior assessment). FSH, LH, AMH, E2 (FXPOI assessment). EEG (epilepsy screening). Echocardiography (assessment of mitral valve prolapse).
Currently, fundamental treatment of fragile X syndrome (restoring lost FMRP) has not reached the clinical application stage. Treatment aims at symptom management and functional improvement.
For ADHD, stimulants such as methylphenidate and amphetamine are effective, and clonidine and guanfacine are also used in some. For anxiety, selective serotonin reuptake inhibitors (SSRIs: fluoxetine, sertraline, etc.) are used, and a reduction in social anxiety has been reported in males with fragile X. Anticonvulsants such as carbamazepine and lamotrigine are used for epilepsy. Atypical antipsychotics (risperidone, aripiprazole) are used for aggressive and self-injurious behavior. Clinical trials of mGluR5 antagonists (AFQ056, RO4917523, etc.) have been conducted in children and adolescents but have not shown consistent results.
Speech therapy starts early in childhood and trains language development, speech intelligibility, and communication strategies. Occupational therapy focuses on sensory processing abnormalities, fine motor skills, and improving independence in daily activities. Special education is conducted in inclusive education or special classes after establishing an individualized education program (IEP). Applied behavior analysis (ABA) is used to manage autism spectrum symptoms.
There is no established disease-modifying therapy. Primidone and propranolol are used for intention tremor. Clonazepam is used adjunctively for anxiety and tremor. Some case reports suggest that immunomodulatory therapy (IVIG, steroids) somewhat slowed progression. Function is maintained through rehabilitation (physical therapy, walking aids).
Estrogen-progestin hormone replacement therapy prevents osteoporosis and maintains cardiovascular health. When pregnancy is desired, ART (assisted reproductive technology) or oocyte donation is considered. Early oocyte cryopreservation for fertility preservation is recommended.
The prognosis of full-mutation males (FXS) depends on the severity of intellectual disability. Most have difficulty living independently and need lifelong support. With appropriate early intervention, education, and therapy, functional abilities (communication, self-care, vocational training) can improve significantly. Life expectancy is close to the normal range in the absence of complications (epilepsy, heart defects, etc.). However, complications such as severe self-injurious behavior, status epilepticus, and gastrointestinal problems can affect life expectancy.
Full-mutation females have a mild phenotype, and most can live independently. However, anxiety, mood disorders, and social difficulties affect quality of life. Fertility may be reduced through FXPOI, and hormone replacement and ART are helpful.
FXTAS is a progressive disease in which tremor, ataxia, and cognitive decline worsen over about 5–25 years after onset. When diagnosed at an advanced age, considerable functional decline may already be present. The risk of falls is high, and in the end stage, severe movement disorder and dementia lead to complete dependence. Earlier onset and a larger premutation repeat number tend to be associated with more severe FXTAS.
Primary prevention of fragile X syndrome is partly possible through genetic counseling for families of premutation carriers and prenatal/preimplantation genetic testing.
Professional genetic counseling is provided to individuals and families in whom an FMR1 mutation has been identified. When a female premutation carrier plans a pregnancy, the likelihood of transmitting a full mutation to a child is calculated based on repeat number and explained. With a repeat number of 55–59, the risk of a full mutation in the child is low, but with 100 or more, a full mutation is transmitted to almost all children.
FMR1 CGG repeat number is measured in fetal DNA by chorionic villus sampling (CVS, 10–12 weeks of gestation) or amniocentesis (15–20 weeks of gestation). PCR and Southern blot are used together to determine repeat size and methylation status. Depending on the results of prenatal diagnosis, continuation or termination of pregnancy is decided through shared decision-making.
After in vitro fertilization, FMR1 analysis is performed at the blastocyst stage, and embryos without a full mutation are selected and transferred. When infertility is present in a female premutation carrier, a combined approach of ART and PGT-M is needed.
When a carrier is identified in a family, screening of other family members is recommended, and early developmental screening is performed in at-risk groups to diagnose fragile X syndrome early and start early intervention programs. For early detection of FXTAS, regular neurological follow-up after age 50 is recommended for male premutation carriers.